The Albanese Government confirmed its decision to defer the bigger decisions, or any decisions, on the Health Technology Assessment Review and signalled a push to lock in new cost‑recovery and agreement arrangements within the next 12 months. A vaguely worded commitment on biosimilars. …
Budget confirms what we already knew and what we had guessed. What a surprise
May 12, 2026 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast - Series 5. Ep.29
August 21, 2026 - - Podcast -
IDT Australia targets profitability after reporting sharply narrowing loss
August 21, 2026 - - Latest News -
Opportunity #5 - From the hardest thing to secure to the easiest thing to get right
August 21, 2026 - - Latest News -
Biogen bolsters leadership ranks as it sharpens focus on patient access and innovation
August 21, 2026 - - Latest News -
Advent moves to acquire majority stake in NZCR Group
August 21, 2026 - -
Personalised mRNA cancer therapy clears Phase 3 milestone in resected melanoma
August 21, 2026 - - Latest News -
New Zealand researchers honoured for work tackling superbugs and blood cancer
August 20, 2026 - - Latest News